The DOI matches its Crossref record, with a small difference in title or year; 21 of the 21 references it cites were found in a registry or an index.
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Open accessAbstract
This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2005
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.
Hedley, A. A., Ogden, C., Johnson, C. L., Carroll, M., Curtin, L. R., & Flegal, K. (2004) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.291.23.2847 · Cited by 4,670
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Self-citationGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P., Ghatei, M. A., Malik, I., Bloom, S. R., & Wilding, J. P. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8738 · Cited by 535
Self-citationOxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 475
Self-citation
Cited by
Sorted by citations
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Though small clinical studies have suggested that oxyntomodulin may be effective for weight loss (Wynne et al., 2005), clinical studies of dual GLP1R/GCGR agonists or triple GLP1R/ GIPR/GCGR have not been reported as of this writing.”
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Gut Hormones and Appetite Control
Wren, A., & Bloom, S. R. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.048 · Cited by 453
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Self-citationGastrointestinal hormones regulating appetite
Chaudhri, O. B., Small, C. J., & Bloom, S. R. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 362
Self-citationSatiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 366
Gastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 344
Self-citationThe role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 282
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Self-citationThe effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F. M., Gribble, F. M., & Park, A. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 276
Self-citationCrespo, C. S., Cachero, A. P., Puebla, L., Barrios, V., & Arilla, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00058 · Cited by 274
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Gut Peptides in the Regulation of Food Intake and Energy Homeostasis
Murphy, K. G., Dhillo, W. S., & Bloom, S. R. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0028 · Cited by 248
Self-citationHenderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat‐Durebex, C., Ananthakrishnan, G., Rohner‐Jeanrenaud, F., Drucker, D. J., DiMarchi, R. D., et al. (2012) · Diabetes · doi:10.2337/db11-1556 · Cited by 240
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 237
Appetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2011.21 · Cited by 229
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 215
Self-citationThe role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 217
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Obesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 188
The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 196
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 176
Appetite signaling: From gut peptides and enteric nerves to brain
Näslund, E. B., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 181
Bowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
Self-citationMalnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment
Nicolini, A., Ferrari, P., Masoni, M. C., Fini, M., Pagani, S., Giampietro, O., & Carpi, A. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.08.005 · Cited by 178
The role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R., Tan, T., & Bewick, G. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 180
Potential Hormone Mechanisms of Bariatric Surgery
Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0276-5 · Cited by 172
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 169
Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
Gastrointestinal targets of appetite regulation in humans
Delzenne, N. M., Blundell, J. E., Brouns, F. J. P. H., Cunningham, K., de Graaf, K. C., Erkner, A., Lluch, A., Mars, M., Peters, H. P. F., & Westerterp‐Plantenga, M. S. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00707.x · Cited by 172
Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones
El‐Salhy, M., Hatlebakk, J. G., & Hausken, T. (2019) · Nutrients · doi:10.3390/nu11081824 · Cited by 160
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
Emerging Therapeutic Strategies for Obesity
Foster‐Schubert, K. E., & Cummings, D. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0041 · Cited by 140
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142
Minireview: Glucagon in Stress and Energy Homeostasis
Jones, B. J., Tan, T., & Bloom, S. R. (2012) · Endocrinology · doi:10.1210/en.2011-1979 · Cited by 144
Self-citationGut hormones: Implications for the treatment of obesity
Neary, M. T., & Batterham, R. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.005 · Cited by 140
Obesity and the role of gut and adipose hormones in female reproduction
Gosman, G. G., Katcher, H. I., & Legro, R. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml024 · Cited by 138
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138
Laferrère, B., Swerdlow, N. J., Bawa, B., Arias, S., Bose, M., Oliván, B., Teixeira, J. A., McGinty, J., & Rother, K. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2767 · Cited by 132
Jørgensen, R., Kubale, V., Vrecl, M., Schwartz, T. W., & Elling, C. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120006 · Cited by 132
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 139
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
How functional foods play critical roles in human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2012) · Food Science and Human Wellness · doi:10.1016/j.fshw.2012.10.001 · Cited by 134
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 129
The future role of gut hormones in the treatment of obesity
Troke, R., Tan, T., & Bloom, S. R. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 128
Self-citationAppetite Regulation: An Overview
Dhillo, W. S. (2007) · Thyroid · doi:10.1089/thy.2007.0018 · Cited by 127
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Miller, G. D. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 132
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Evers, S. S., Sandoval, D. A., & Seeley, R. J. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034423 · Cited by 120
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Druce, M. R. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2005.073759 · Cited by 116
Field, B. C. T., Wren, A., Peters, V., Baynes, K., Martin, N. M., Patterson, M., Alsaraf, S., Amber, V., Wynne, K., Ghatei, M. A., et al. (2010) · Diabetes · doi:10.2337/db09-1859 · Cited by 113
Self-citationGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 108
Behary, P., Tharakan, G., Αλεξιάδου, Κ., Johnson, N. A., Albrechtsen, N. J. W., Kenkre, J. S., Cuenco, J., Hope, D. C. D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 115
Self-citationMedical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Diet in irritable bowel syndrome
El‐Salhy, M., & Gundersen, D. (2015) · Nutrition Journal · doi:10.1186/s12937-015-0022-3 · Cited by 115
Mechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105
Monteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 108
Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids
Alhabeeb, H., AlFaiz, A., Kutbi, E., AlShahrani, D. A., Alsuhail, A., Alrajhi, S., Alotaibi, N., Alotaibi, K., Alamri, S. S., Alghamdi, S. A. A., et al. (2021) · Nutrients · doi:10.3390/nu13020481 · Cited by 112
The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin
Kosinski, J. R., Hubert, J. A., Carrington, P. E., Chicchi, G. G., Mu, J., Miller, C., Cao, J., Bianchi, E., Pessi, A., SinhaRoy, R., et al. (2012) · Obesity · doi:10.1038/oby.2012.67 · Cited by 103
The mechanisms of weight loss after bariatric surgery
Tadross, J. A., & le Roux, C. W. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.14 · Cited by 105
Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Changes in gut hormones after bariatric surgery
Vincent, R. P., & Le Roux, C. W. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03164.x · Cited by 100
Scott, W. R., & Batterham, R. L. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00038.2011 · Cited by 101
Gut hormones and appetite control
Hameed, S., Dhillo, W. S., & Bloom, S. R. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2008.01492.x · Cited by 102
Self-citationEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Is irritable bowel syndrome an organic disorder?
El‐Salhy, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.384 · Cited by 95
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 92
Hormonal Regulators of Appetite
Austin, J., & Marks, D. L. (2008) · International Journal of Pediatric Endocrinology · doi:10.1155/2009/141753 · Cited by 123
Neuropeptide Y and peptide YY: important regulators of energy metabolism
Nguyen, A., Herzog, H., & Sainsbury, A. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283422f0a · Cited by 92
Parkinson, J. R. C., Chaudhri, O. B., Kuo, Y., Field, B. C. T., Herlihy, A. H., Dhillo, W. S., Ghatei, M. A., Bloom, S. R., & Bell, J. D. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.09.047 · Cited by 89
Self-citationBagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2335 · Cited by 91
Gut–Brain Axis: Regulation of Glucose Metabolism
Heijboer, A. C., Pijl, H., van den Hoek, A. M., Havekes, L. M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01492.x · Cited by 91
Chaudhri, O. B., Parkinson, J. R. C., Kuo, Y., Druce, M. R., Herlihy, A. H., Bell, J. D., Dhillo, W. S., Stanley, S. A., Ghatei, M. A., & Bloom, S. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.033 · Cited by 87
Self-citationProglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Sinclair, E. M., & Drucker, D. J. (2005) · Physiology · doi:10.1152/physiol.00030.2005 · Cited by 93
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 89
The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control
Wynne, K., & Bloom, S. R. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0318 · Cited by 84
Self-citationLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 84
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., MINNION, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M. J., Beale, K., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2008) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84
Self-citationJouy, S. H., Mohan, S., Scichilone, G., Mostafa, A., & Mahmoud, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12092129 · Cited by 96
The hypothalamus, hormones, and hunger: alterations in human obesity and illness
Goldstone, A. P. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)53003-1 · Cited by 87
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Department of Dietetics, Imperial College Faculty of Medicine, Hammersmith Hospital, London, U.K
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2390-2395
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154497567
- Cited by
- 435
- References
- 21
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 17 · 2023: 24 · 2022: 10 · 2021: 24 · 2020: 22 · 2019: 16 · 2018: 26 · 2017: 17 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 31 · 2012: 26
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, obesity, weight loss, subcutaneous administration, energy intake, leptin, adiponectin, adipose tissue, anorectic effect, palatability, appetite regulation
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Blood Glucose, Body Composition, Energy Intake, Diet, Double-Blind Method, Eating, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Insulin, Kinetics, Male, Middle Aged, Obesity, Self Administration, Weight Loss, Exercise, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
